Inquiry Basket
Loading ......
The term liquid biopsy describes the analysis of material shed by tissues into accessible body fluids, offering a window onto physiology and disease without invasive sampling. Within this field, exosomes have attracted attention as a particularly informative sample type. Protected by a lipid bilayer and released by most cells, they carry a concentrated snapshot of the parent cell's proteins and nucleic acids into blood, urine, saliva, cerebrospinal fluid, and other biofluids. Because their cargo can change in response to cellular stress, activation, or transformation, exosomes have become a focus of efforts to detect disease earlier, monitor its course, and measure treatment response.
Among the attractions of exosomes as biomarkers is the stability of their cargo. The surrounding phospholipid bilayer shields the enclosed proteins and RNA from the nucleases and proteases present in extracellular fluid, so the molecular signature inside a vesicle can remain intact far longer than the same molecules would survive in free circulation. This protection matters for diagnostics because it preserves information that would otherwise degrade rapidly after sample collection. Exosomes are also abundant and can be isolated from a wide range of biofluids with only modest volumes, making repeated sampling feasible for monitoring. Their presence in fluids that are otherwise difficult to access, such as cerebrospinal fluid, opens diagnostic possibilities for conditions of the nervous system that lack good peripheral markers. The practical upshot is a sample type that is both information-rich and resilient, two qualities that are highly valued when designing tests meant to perform reliably outside specialized centers.
Figure 1. Biogenesis, secretion, and uptake of exosomes. (Source: Zhang S, et al. 2024)
Research has shown that the molecular content of exosomes tends to mirror the state of the cells that released them, so that vesicles from a diseased tissue carry signatures distinct from those of healthy tissue. In oncology, exosomal proteins and nucleic acids have been identified that distinguish tumor-bearing individuals from healthy controls and that track with tumor type and burden. Similar logic applies to neurodegenerative conditions, where vesicles recovered from cerebrospinal fluid carry species linked to neuronal injury and protein aggregation. In prenatal medicine, vesicles circulating in maternal blood originate in part from the placenta and fetus, providing a non-invasive source of information about fetal and placental health. Infectious processes and transplanted organs likewise leave molecular traces in vesicle populations. The breadth of these observations reflects a general principle: because exosomes sample the secretory output of many tissues, their cargo can serve as a composite readout of physiological state across multiple organ systems.
Figure 2. Biogenesis, secretion, composition, and application of exosomes as liquid biopsy. (Source: Zhou B, et al. 2020)
Exosomes do not replace other liquid-biopsy approaches but add a distinct dimension to them. Circulating tumor DNA reveals genetic alterations released from dying cells, and circulating tumor cells provide information about intact malignant cells, yet both can be scarce or intermittent. Exosomes are continuously secreted by living cells, so they report on ongoing cellular activity rather than only on cell death, and they are present at high numbers even when tumor burden is low. Their cargo spans proteins, RNA, and lipids, offering multiple layers of information from a single sample. This complementarity means that exosome-based measurements are often most powerful when combined with other markers in a panel, each contributing a different facet of the disease picture. For researchers building assays, the value lies in selecting the combination of vesicle-derived and free analytes that together give the clearest signal.
The greatest barrier to clinical adoption of exosome diagnostics is not the biology but the variability introduced before analysis even begins. The way a sample is collected, the tubes and anticoagulants used, the time and temperature of storage, and the method chosen to isolate vesicles each influence the composition of what is ultimately measured. A vesicle population prepared by one separation approach can differ markedly from one prepared by another, and small differences in handling can shift the apparent abundance of a marker. These pre-analytical effects make it difficult to compare results across studies and to set reliable thresholds for clinical use. Position papers from the extracellular-vesicle field have therefore called for detailed reporting of sample origin, collection, storage, and separation, together with characterization of the isolated vesicles by accepted markers, so that measurements become comparable between laboratories. Establishing such harmonized procedures is a prerequisite for any test that will be used to make medical decisions.
Translating exosome diagnostics into routine care depends on converting promising signatures into validated, reproducible assays. Multi-marker panels that combine several vesicle-derived species tend to perform better than any single marker, because disease signals are typically distributed across many molecules. Robust reference materials and well-characterized controls are needed so that a positive result means the same thing in different laboratories and at different times. Equally important is independent validation in large, well-defined cohorts, since a marker that performs well in a small discovery set may not hold up in broader populations. As standardization improves and panels are refined, exosome-based tests are expected to find their earliest firm footing in areas where conventional markers are weak, such as early detection of difficult tumors, monitoring of neurological disease, and non-invasive assessment of fetal and transplant status. The trajectory is clear: exosomes offer a uniquely protected and informative sample type whose clinical value will be realized through disciplined analytical rigor.
Although blood is the most studied biofluid for exosome diagnostics, other samples offer advantages for specific applications. Urine provides a non-invasive source rich in vesicles shed by the kidney and urinary tract, making it attractive for renal and urological conditions where blood markers are indirect. Saliva is similarly accessible and reflects oral and salivary-gland physiology, while amniotic fluid and other gestation-associated samples can reveal placental and fetal information without invasive procedures. Each fluid brings its own baseline of vesicle abundance, contaminating proteins, and stability profile, so the analytical strategy must be matched to the matrix. The existence of these alternatives broadens the reach of exosome-based testing into settings where drawing blood is inconvenient or where the disease is localized to an organ that sheds few vesicles into circulation. Choosing the right biofluid is therefore a strategic decision that shapes both the sensitivity of the test and the ease with which samples can be collected at scale.
Exosomes occupy a distinctive place in the liquid-biopsy landscape, combining the stability of a membrane-protected package with the breadth of a multi-molecular readout drawn from living cells. Their cargo can reflect the physiology of tumors, neurons, placenta, pathogens, and transplanted tissue, making them relevant across an unusually wide range of conditions. The science that supports their diagnostic use is sound; the remaining work is largely methodological, centered on controlling pre-analytical variation and agreeing on how vesicles and their markers should be measured and reported. With those foundations in place, exosome-based diagnostics are positioned to extend the reach of non-invasive testing into settings where current options are limited, and to do so using material that the body itself provides.
References
| Target | Cat. No. | Product Name | Expression System | Tag/Conjugate | Application | |
| Exosome | DAGA-987 | Purified exosomes from plasma of healthy donors | Plasma of healthy donors | Unconjugated | Calibration, Control, Flow cytometry, EM | Inquiry |
| DAGA-988 | Purified exosomes from urine of healthy donors | Urine of healthy donors | Unconjugated | Calibration, Control, Flow cytometry, EM | Inquiry | |
| DAGA-989 | Purified exosomes from COLO1 cell culture supernatant | Human Colon Carcinoma cell line COLO1 | Unconjugated | Calibration, Control, Flow cytometry, EM | Inquiry | |
| DAGA-990 | Purified exosomes from MM1 cell culture supernatant | Human Melanoma cell line MM1 | Unconjugated | Calibration, Control, Flow cytometry, EM | Inquiry | |
| DAGA-991 | Purified exosomes from BLCL cell culture supernatant | BLCL21 | Unconjugated | Calibration, Control, Flow cytometry, EM | Inquiry | |
| DAGA-992 | Purified exosomes from HCT116 cell culture supernatant | Human Colon Carcinoma cell line HCT116 | Unconjugated | Calibration, Control, Flow cytometry, EM | Inquiry | |
| DAGA-993 | Purified exosomes from U87 MG cell culture supernatant | Human Glioblastoma-Astrocytoma cell line U87 MG | Unconjugated | Calibration, Control, Flow cytometry, EM | Inquiry | |
| DAGA-994 | Purified exosomes from SK-N-SH cell culture supernatant | Human Neuroblastoma cell line SK-N-SH | Unconjugated | Calibration, Control, Flow cytometry, EM | Inquiry | |
| DAGA-995 | Purified exosomes from PC3 cell culture supernatant | Human Prostate adenocarcinoma grade IV cell line PC3 | Unconjugated | Calibration, Control, Flow cytometry, EM | Inquiry | |
| DAGA-996 | Purified exosomes from BPH-1 cell culture supernatant | Human being prostatic hyperplasia cell line BPH-1 | Unconjugated | Calibration, Control, Flow cytometry, EM | Inquiry | |
| DAGA-997 | Purified exosomes from DAUDI cell culture supernatant | Human Burkitt Lymphoma cell line DAUDI | Unconjugated | Calibration, Control, Flow cytometry, EM | Inquiry | |
| DAGA-998 | Purified exosomes from A549 cell culture supernatant | Lung carcinoma cell line A549 | Unconjugated | Calibration, Control, Flow cytometry, EM | Inquiry | |
| DAGA-999 | Purified exosomes from K562 cell culture supernatant | Pleural effusion, leukemia chronic myelogenous cell line K562 | Unconjugated | Calibration, Control, Flow cytometry, EM | Inquiry | |
| DAGA-1000 | Purified exosomes from B16F10 mouse cell culture supernatant | Mouse melanoma cell line B16F10 | Unconjugated | Calibration, Control, Flow cytometry, EM | Inquiry | |
| DAGA-1001 | Purified exosomes from serum of healthy donors | Serum of healthy donors | Unconjugated | Calibration, Control, Flow cytometry, EM | Inquiry | |
| DAGA-1002 | Purified exosomes from saliva of healthy donors | Saliva of healthy donors | Unconjugated | Calibration, Control, Flow cytometry, EM | Inquiry | |
| DAGA-1003 | Fluorescent labeled Exosome Standards | N/A | FITC | Fluorescence microscopy, Flow cytometry, EM | Inquiry | |
| DAG-WT3255 | Purified exosomes from HEK293 cell line | HEK293 cells | N/A | Calibration, Control, Flow cytometry, EM | Inquiry | |
| DAG-WT1158 | Purified exosomes from MSC | MSC from Adipose tissue | N/A | Calibration, Control, Flow cytometry, EM | Inquiry |
Loading ......
